Tags

Type your tag names separated by a space and hit enter

Testicular Malignancies

Testicular Malignancies is a topic covered in the 5-Minute Clinical Consult.

To view the entire topic, please or purchase a subscription.

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:

Medicine Central

-- The first section of this topic is shown below --

Basics

Description

  • Testicular cancer accounts for <1% of all cancers in men; it is the most common solid malignancy in men aged 20 to 34 years (1).
  • An estimated 9,310 new cases were diagnosed, and an estimated 400 deaths occurred in the United States in 2018 (2).
  • Rates for new cases have been rising 0.8% each year over the last 10 years, but death rates have been stable.
  • The median age at diagnosis is 33 years. The median age at death is 42 years (2).
  • Treatment produces an overall 5-year survival of 95.3%; for African American patients, this 5-year survival rate is alarmingly lower but has improved from 86% to 90% (2).

Etiology and Pathophysiology

95% of all malignant tumors arising in the testes are germ cell tumors (GCTs), which are subclassified as follows:

  • Seminomatous GCTs: most common type overall
  • Nonseminomatous GCTs (NSGCTs): These include embryonal cell carcinoma, choriocarcinoma, yolk sac tumor, teratomas, or often multiple cell types; these are more clinically aggressive tumors.

Risk Factors

  • Cryptorchidism is the most firmly established risk factor: Relative risk of testicular cancer in all patients with cryptorchidism is 3 to 8, with a lower relative risk of 2 to 3 in those undergoing orchiopexy by age 12 years; in patients with unilateral cryptorchidism, the relative risk of testicular cancer in the contralateral normally descended testis is negligible (3).
  • Personal history of testicular cancer
  • Use of muscle building supplements
  • Positive family history for testicular cancer
  • Testicular dysgenesis
  • Klinefelter syndrome
  • Caucasian race
  • HIV infections

General Prevention

No evidence that screening for testicular cancer is effective (4)

-- To view the remaining sections of this topic, please or purchase a subscription --

Citation

Stephens, Mark B., et al., editors. "Testicular Malignancies." 5-Minute Clinical Consult, 27th ed., Wolters Kluwer, 2019. Medicine Central, im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116591/0.1/Testicular_Malignancies.
Testicular Malignancies. In: Stephens MB, Golding J, Baldor RA, et al, eds. 5-Minute Clinical Consult. 27th ed. Wolters Kluwer; 2019. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116591/0.1/Testicular_Malignancies. Accessed June 27, 2019.
Testicular Malignancies. (2019). In Stephens, M. B., Golding, J., Baldor, R. A., & Domino, F. J. (Eds.), 5-Minute Clinical Consult. Available from https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116591/0.1/Testicular_Malignancies
Testicular Malignancies [Internet]. In: Stephens MB, Golding J, Baldor RA, Domino FJ, editors. 5-Minute Clinical Consult. Wolters Kluwer; 2019. [cited 2019 June 27]. Available from: https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116591/0.1/Testicular_Malignancies.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Testicular Malignancies ID - 116591 ED - Stephens,Mark B, ED - Golding,Jeremy, ED - Baldor,Robert A, ED - Domino,Frank J, BT - 5-Minute Clinical Consult, Updating UR - https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116591/0.1/Testicular_Malignancies PB - Wolters Kluwer ET - 27 DB - Medicine Central DP - Unbound Medicine ER -